Compare CarMax, Inc (KMX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Regeneron Pharmaceuticals Inc — how do they compare? CarMax, Inc trades at $58.03 (market cap $8.34B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 10× CarMax, Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| KMX | REGN | |
|---|---|---|
Market Cap | $8.34B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $62.17 | $812.27 |
52-Week Low | $30.88 | $555.51 |
Enterprise Value | $26.85B | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $58.18, up 0.21% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance, beating expectations in Q3 2025 and Q1 2026 but missing in Q2 2025. Revenue has declined from $31.9B in 2022 to $26.35B in 2025, while net income margin improved slightly to 1.89%. Recent news includes partnerships to enhance customer experience and ongoing legal investigations into fiduciary duties.
Outlook is cautious with a consensus price target of $53.09 below the current price, indicating potential downside. Opportunities lie in operational improvements and AI integrations, but risks include high debt, competitive pressures, and legal scrutiny. Analyst sentiment is neutral with 68.58% hold ratings, suggesting wait-and-see approach amid volatility.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
